Surmodics (NASDAQ: SRDX) has announced outcomes from an analysis of 160 real-world patients with symptomatic infrainguinal limb ischemia in the PROWL registry study evaluating its Pounce thrombectomy platform.
The results were presented yesterday at the 23rd Annual VIVA Conference in Las Vegas, NV, by PROWL national co-principal investigators Dr. Sean Lyden and Dr. Joseph Campbell, as well as study investigator Dr. Peter Monteleone.
In a statement, Dr. Campbell commented, “As reflected in the all-comers PROWL registry, a large share of PAD patients who require prompt removal of arterial blood clots have experienced symptoms well beyond two weeks. The exclusion of these patients from other studies of peripheral arterial thrombectomy is a serious limitation, as thrombus becomes more organized with age and increasingly resistant to thrombolytics and aspiration-based devices. Findings from the PROWL registry show that the Pounce Thrombectomy Platform is an effective, rapid, low-risk option for front-line endovascular treatment of limb ischemia across the diverse populations we see in clinical practice.”
Dr. Lyden added, “Real-world thromboembolic patients present with numerous uncontrollable factors, including tremendous variability in lesion characteristics and locations, medical history, symptom duration, and urgency. Data from the PROWL registry demonstrate that this device effectively addresses this variability, achieving rapid, efficient clot removal across a broad spectrum of clot chronicity and patient comorbidities. In nearly 80% of patients, no additional clot removal was required following use of the device, and procedural success exceeded 90%, outcomes that can translate to shorter procedure times, and reduced risk of complications.”
